Connection
Charles Edelstein to Dose-Response Relationship, Drug
This is a "connection" page, showing publications Charles Edelstein has written about Dose-Response Relationship, Drug.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.221 |
|
|
|
-
Holditch SJ, Brown CN, Atwood DJ, Lombardi AM, Nguyen KN, Toll HW, Hopp K, Edelstein CL. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease. Am J Physiol Renal Physiol. 2019 07 01; 317(1):F187-F196.
Score: 0.108
-
Ozkok A, Ravichandran K, Wang Q, Ljubanovic D, Edelstein CL. NF-?B transcriptional inhibition ameliorates cisplatin-induced acute kidney injury (AKI). Toxicol Lett. 2016 Jan 05; 240(1):105-13.
Score: 0.085
-
Edelstein CL, Yaqoob MM, Alkhunaizi AM, Gengaro PE, Nemenoff RA, Wang KK, Schrier RW. Modulation of hypoxia-induced calpain activity in rat renal proximal tubules. Kidney Int. 1996 Oct; 50(4):1150-7.
Score: 0.023
-
Klezovitch O, Edelstein C, Scanu AM. Evidence that the fibrinogen binding domain of Apo(a) is outside the lysine binding site of kringle IV-10: a study involving naturally occurring lysine binding defective lipoprotein(a) phenotypes. J Clin Invest. 1996 Jul 01; 98(1):185-91.
Score: 0.006